ABIVAX SA-ADR (ABVX) Fundamental Analysis & Valuation

NASDAQ:ABVX • US00370M1036

Current stock price

123.03 USD
-0.96 (-0.77%)
At close:
123.025 USD
0 (0%)
After Hours:

This ABVX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ABVX Profitability Analysis

1.1 Basic Checks

  • In the past year ABVX has reported negative net income.
  • ABVX had a negative operating cash flow in the past year.
  • ABVX had negative earnings in each of the past 5 years.
  • ABVX had a negative operating cash flow in each of the past 5 years.
ABVX Yearly Net Income VS EBIT VS OCF VS FCFABVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • ABVX's Return On Assets of -146.87% is on the low side compared to the rest of the industry. ABVX is outperformed by 84.17% of its industry peers.
Industry RankSector Rank
ROA -146.87%
ROE N/A
ROIC N/A
ROA(3y)-70.48%
ROA(5y)-60.32%
ROE(3y)-451.51%
ROE(5y)-460.64%
ROIC(3y)N/A
ROIC(5y)N/A
ABVX Yearly ROA, ROE, ROICABVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

  • ABVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABVX Yearly Profit, Operating, Gross MarginsABVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. ABVX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ABVX has more shares outstanding
  • Compared to 5 years ago, ABVX has more shares outstanding
  • ABVX has a worse debt/assets ratio than last year.
ABVX Yearly Shares OutstandingABVX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ABVX Yearly Total Debt VS Total AssetsABVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 19.26 indicates that ABVX is not in any danger for bankruptcy at the moment.
  • ABVX has a Altman-Z score of 19.26. This is amongst the best in the industry. ABVX outperforms 88.42% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 19.26
ROIC/WACCN/A
WACCN/A
ABVX Yearly LT Debt VS Equity VS FCFABVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

  • A Current Ratio of 0.77 indicates that ABVX may have some problems paying its short term obligations.
  • ABVX has a worse Current ratio (0.77) than 88.42% of its industry peers.
  • A Quick Ratio of 0.77 indicates that ABVX may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.77, ABVX is doing worse than 87.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.77
ABVX Yearly Current Assets VS Current LiabilitesABVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ABVX Growth Analysis

3.1 Past

  • ABVX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.52%, which is quite good.
EPS 1Y (TTM)18.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-69.31%

3.2 Future

  • ABVX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -8.10% yearly.
  • Based on estimates for the next years, ABVX will show a very strong growth in Revenue. The Revenue will grow by 171.60% on average per year.
EPS Next Y-20.7%
EPS Next 2Y33.3%
EPS Next 3Y-1.13%
EPS Next 5Y-8.1%
Revenue Next Year29.38%
Revenue Next 2Y13.87%
Revenue Next 3Y266.42%
Revenue Next 5Y171.6%

3.3 Evolution

ABVX Yearly Revenue VS EstimatesABVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
ABVX Yearly EPS VS EstimatesABVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. ABVX Valuation Analysis

4.1 Price/Earnings Ratio

  • ABVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABVX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABVX Price Earnings VS Forward Price EarningsABVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150 -200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABVX Per share dataABVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.3%
EPS Next 3Y-1.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ABVX Dividend Analysis

5.1 Amount

  • No dividends for ABVX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ABVX Fundamentals: All Metrics, Ratios and Statistics

ABIVAX SA-ADR

NASDAQ:ABVX (3/19/2026, 6:42:23 PM)

After market: 123.025 0 (0%)

123.03

-0.96 (-0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-15
Earnings (Next)03-23
Inst Owners39.91%
Inst Owner Change9.18%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap9.73B
Revenue(TTM)N/A
Net Income(TTM)-176.24M
Analysts85.71
Price Target154.7 (25.74%)
Short Float %4.29%
Short Ratio2.63
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.39%
PT rev (3m)23.83%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-15.66%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-32.45%
Revenue NY rev (3m)-32.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.58
EYN/A
EPS(NY)-0.55
Fwd EYN/A
FCF(TTM)-1.97
FCFYN/A
OCF(TTM)-1.97
OCFYN/A
SpS0
BVpS-0.7
TBVpS-1.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -146.87%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.48%
ROA(5y)-60.32%
ROE(3y)-451.51%
ROE(5y)-460.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.77
Altman-Z 19.26
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)54.18%
Cap/Depr(5y)310.65%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.26%
EPS Next Y-20.7%
EPS Next 2Y33.3%
EPS Next 3Y-1.13%
EPS Next 5Y-8.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-69.31%
Revenue Next Year29.38%
Revenue Next 2Y13.87%
Revenue Next 3Y266.42%
Revenue Next 5Y171.6%
EBIT growth 1Y-35.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.04%
EBIT Next 3Y16%
EBIT Next 5Y40.7%
FCF growth 1Y-141.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-142.43%
OCF growth 3YN/A
OCF growth 5YN/A

ABIVAX SA-ADR / ABVX Fundamental Analysis FAQ

What is the fundamental rating for ABVX stock?

ChartMill assigns a fundamental rating of 1 / 10 to ABVX.


What is the valuation status of ABIVAX SA-ADR (ABVX) stock?

ChartMill assigns a valuation rating of 0 / 10 to ABIVAX SA-ADR (ABVX). This can be considered as Overvalued.


How profitable is ABIVAX SA-ADR (ABVX) stock?

ABIVAX SA-ADR (ABVX) has a profitability rating of 0 / 10.


Can you provide the financial health for ABVX stock?

The financial health rating of ABIVAX SA-ADR (ABVX) is 2 / 10.